Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy
about
Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.Economic impact of biologic utilization patterns in patients with psoriatic arthritisAnnual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.Antidrug antibodies in psoriasis: a systematic review.Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.Systemic therapies for psoriasis: an evidence-based update.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy.Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios.Moderate to severe psoriasis treatment challenges through the era of biological drugs.Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use.Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study.Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
P2860
Q33785083-0D6228B7-80A8-4DA1-B18C-B5FCE9F8C9BEQ33840422-FD76B395-4050-49B2-9EA0-B3CFEC61197AQ34944668-A22AD76D-E33E-4E10-A14E-E49EB4CF9A29Q37095210-EE756E67-4CED-4480-8DB6-96A805329AC3Q37631750-70551AD1-6290-453D-B7AB-8D9AA8170031Q38084325-1467E595-87A1-447C-B17A-0CB0C44887C2Q38151757-900EDCEB-A97E-4E7D-8539-4A8412E6E4C3Q38166663-2AAE65D2-34AD-4B84-AE92-BEDBA1D1D76AQ38185297-2B8FA884-1E16-46A9-90B4-BF756B41AB8FQ38537167-A9F66294-218A-4823-B283-F44D6A6C81F2Q38594683-1983B570-8910-4BF9-A5D4-D0E2077148EEQ38611360-0407BE1B-F6C3-405D-BA4B-6EC6E628EC9EQ38965214-792A50E4-7477-4704-BB1E-75AD5266F40DQ40045451-5B9E4701-F3B3-4977-AF49-5EF47E625E97Q40437510-3D1F4D1E-D755-4050-8CA7-2E274B5CF28DQ41861093-D14715D3-3EF2-4520-B503-2F31A0EC8D00Q42646805-F779C3E1-2644-4FB6-8D6C-E8AD846FDAC1Q44249426-7EA5BB15-A983-479A-A146-211100D3F4EFQ46452013-3E932E56-BBFC-4505-9471-DBB329B4E90BQ47689590-5DA891A1-6B0D-4782-9839-98918980BC04Q47873720-A251C4F4-33C0-433B-8734-15C0F61E954FQ48059175-EBE066E3-D59E-49BA-97AD-0188EA143438Q51826173-BCCB8CC8-FA05-40EC-8A21-AC71189091F5Q58800375-CFAFFDA8-AFFB-44CF-A2CF-F61241BD8BF7
P2860
Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Off-label biologic regimens in ...... d interrupted biologic therapy
@ast
Off-label biologic regimens in ...... d interrupted biologic therapy
@en
Off-label biologic regimens in ...... d interrupted biologic therapy
@nl
type
label
Off-label biologic regimens in ...... d interrupted biologic therapy
@ast
Off-label biologic regimens in ...... d interrupted biologic therapy
@en
Off-label biologic regimens in ...... d interrupted biologic therapy
@nl
prefLabel
Off-label biologic regimens in ...... d interrupted biologic therapy
@ast
Off-label biologic regimens in ...... d interrupted biologic therapy
@en
Off-label biologic regimens in ...... d interrupted biologic therapy
@nl
P2860
P31
P1433
P1476
Off-label biologic regimens in ...... d interrupted biologic therapy
@en
P2093
April W. Armstrong
Elizabeth A. Brezinski
P2860
P304
P356
10.1371/JOURNAL.PONE.0033486
P407
P5008
P577
2012-01-01T00:00:00Z
2012-04-11T00:00:00Z